Comparative Pharmacology
Head-to-head clinical analysis: THEOCLEAR L A 130 versus THEOCLEAR 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEOCLEAR L A 130 versus THEOCLEAR 200.
THEOCLEAR L.A.-130 vs THEOCLEAR-200
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to bronchodilation. It also acts as an adenosine receptor antagonist and may enhance diaphragmatic contractility.
Treatment of asthma (FDA-approved)Treatment of chronic obstructive pulmonary disease (COPD) (off-label)
FDA: Treatment of asthma and reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD)
130 mg orally every 12 hours; extended-release tablet.
Theophylline 200 mg orally every 6 hours (extended-release) or as directed by serum theophylline concentrations. Usual adult target: 400-600 mg/day.
None Documented
None Documented
Terminal elimination half-life is 3-8 hours in healthy adults (mean 5-6 hours). It is prolonged in patients with hepatic cirrhosis, heart failure, or COPD (up to 30 hours) and in neonates (20-30 hours). Smoking induces metabolism, reducing half-life to 1-4 hours.
Terminal elimination half-life: ~8 hours (range 3–12 hours) in adults; prolonged in hepatic impairment, heart failure, COPD, and neonates. Significantly shorter in smokers (4–6 hours).
Primarily hepatic via CYP1A2, CYP2E1, and CYP3A4 (major); also N-demethylation and oxidation. Exhibits non-linear pharmacokinetics.
Hepatic via CYP1A2, CYP2E1, and CYP3A4. Follows Michaelis-Menten kinetics with dose-dependent metabolism.
Approximately 90% of theophylline is eliminated hepatically via CYP1A2 and CYP3A4 metabolism; renal excretion of unchanged drug accounts for about 10% in adults, but may increase to 50% in neonates. Biliary/fecal elimination is negligible.
Renal: ~10% unchanged; Hepatic metabolism (CYP1A2, CYP3A4) accounts for ~90% of elimination; metabolites (caffeine, 3-methylxanthine, 1-methyluric acid) excreted renally. Fecal excretion negligible.
Approximately 40% bound to plasma proteins, primarily albumin. Binding is reversible and independent of concentration within therapeutic range.
~40% bound, primarily to albumin.
Vd of 0.3-0.7 L/kg (average 0.5 L/kg) approximates total body water. This indicates extensive distribution into tissues, with higher concentrations in tissues than plasma.
0.3–0.7 L/kg; approx. 0.45 L/kg in adults. Increased Vd in premature infants, cirrhosis, and CHF. Distributes freely into breast milk and across placenta.
Oral bioavailability of the sustained-release formulation approaches 100% due to complete absorption. However, food can affect absorption rate; with Theoclear L.A.-130, high-fat meals may increase peak concentration and rate of absorption.
Oral: 96% (nearly complete). Rectal: variable (70–90%). Intravenous: 100%.
No specific adjustment required; monitor serum concentrations and adjust dose based on clinical response and trough levels.
No specific GFR-based dose adjustments are recommended; however, monitor serum theophylline concentrations in patients with renal impairment as clearance may be reduced.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75% and monitor levels closely.
Child-Pugh Class A: reduce dose by 50%. Child-Pugh Class B: reduce dose by 75%. Child-Pugh Class C: avoid use or use with extreme caution; monitor serum levels frequently. Dose adjustments should be guided by serum theophylline concentrations.
Not recommended for children under 6 years; for children 6-12 years: 130 mg once daily initially, titrate based on weight and serum levels (target 5-15 mcg/mL).
Initial dose: 5 mg/kg orally every 6 hours (immediate-release) or 10-15 mg/kg/day divided every 12 hours (extended-release). Titrate based on serum theophylline levels (target 5-15 mcg/mL). Maximum dose: 16 mg/kg/day up to 400 mg/day for children 1-9 years; 16 mg/kg/day up to 600 mg/day for children 9-16 years.
Initiate at lower end of dosing range (130 mg once daily) and titrate slowly; monitor for toxicity due to reduced clearance.
Start at lowest effective dose (e.g., 200 mg once daily) and titrate slowly. Monitor serum theophylline concentrations closely due to reduced clearance in elderly. Target serum level: 5-10 mcg/mL.
No FDA black box warning.
None
["Risk of seizures and arrhythmias at high serum levels (therapeutic range 10-20 mcg/mL)","Monitor serum theophylline levels regularly","Use caution in patients with peptic ulcer disease, hyperthyroidism, or seizure disorders","May exacerbate arrhythmias; ECG monitoring recommended","Drug interactions with CYP1A2 inhibitors (e.g., cimetidine, fluoroquinolones) and inducers (e.g., smoking, rifampin)"]
["Narrow therapeutic index; serum levels must be monitored to avoid toxicity.","Use with caution in patients with peptic ulcer, seizure disorders, or cardiac arrhythmias.","Coadministration with drugs that affect CYP1A2 (e.g., cimetidine, fluoroquinolones, macrolides) can alter theophylline clearance.","May cause tachycardia, palpitations, and central nervous system stimulation."]
["Hypersensitivity to theophylline or any component","Pre-existing cardiac arrhythmias (e.g., tachyarrhythmias)","Uncontrolled seizure disorder","Active peptic ulcer disease"]
Hypersensitivity to theophylline or any component of the formulation.
Data Pending Review
Data Pending Review
Avoid high-fat meals which may alter absorption of sustained-release tablets. Limit caffeine intake from coffee, tea, cola, and chocolate. Charcoal-grilled foods may increase clearance. No specific dietary restrictions beyond caffeine moderation; maintain consistent diet to avoid fluctuations in drug levels.
Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it can potentiate side effects. Food does not significantly alter absorption, but take with food if gastrointestinal upset occurs. Charcoal-broiled foods may increase metabolism; maintain consistent intake.
Theophylline (THEOCLEAR L.A.-130) is not associated with major teratogenic effects in humans. First trimester exposure does not increase risk of congenital malformations above baseline. Third trimester use may cause neonatal irritability, tachycardia, and vomiting due to transplacental transfer. Risk of fetal respiratory depression is low at therapeutic maternal levels.
FDA Pregnancy Category C. First trimester: Crosses placenta; limited data suggest no major malformations but fetal tachycardia and jitteriness reported. Second and third trimesters: Risk of neonatal apnea, hypoglycemia, and hypocalcemia due to beta-adrenergic stimulation. Avoid during labor due to risk of maternal tachycardia and fetal distress.
Theophylline is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.6-0.7. Infant exposure is about 1-10% of maternal weight-adjusted dose. Adverse effects in nursing infants (irritability, sleep disturbance) have been reported. Caution advised; monitor infant for toxicity.
Excreted in breast milk; milk-to-plasma ratio approximately 0.6-0.7. Considered compatible with breastfeeding but monitor infant for irritability, insomnia, and tachycardia. Accumulation may occur in neonates with reduced clearance.
Pregnancy decreases theophylline clearance (especially third trimester due to decreased hepatic metabolism) and increases volume of distribution. Dose requirements may decrease by 20-30% in later pregnancy. Monitor serum levels and adjust dose to maintain therapeutic range (5-15 mcg/mL). Postpartum clearance returns rapidly (within 2 weeks); dose reduction may be needed to avoid toxicity.
Increase dose by 20-30% in second and third trimesters due to increased clearance and volume of distribution. Monitor levels frequently; postpartum return to prepregnancy dosing within 2 weeks.
Category C
Category C
Theophylline has a narrow therapeutic index (10-20 mcg/mL). Levels >20 mcg/mL increase toxicity risk. Immunoassay cross-reactivity with caffeine and other xanthines may falsely elevate levels. Adjust dose in heart failure, liver disease, and for drug interactions with cimetidine, fluoroquinolones, and macrolides. Smoking induces metabolism requiring dose increase. Sustained-release formulations should not be crushed or chewed.
Theophylline has a narrow therapeutic index (5-15 mcg/mL); levels >20 mcg/mL increase toxicity risk. Use with caution in patients with hepatic impairment, heart failure, or fever, as clearance is reduced. Cimetidine, ciprofloxacin, and macrolides increase theophylline levels; monitor levels and adjust dose. Smoking induces metabolism; require higher doses. Consider drug interactions with CYP1A2 inhibitors/inducers. Serum theophylline levels should be monitored at steady state and with any change in medication or condition.
Do not crush or chew sustained-release tablets; swallow whole.Take exactly as prescribed; do not double doses if missed.Avoid excessive caffeine (coffee, tea, cola, chocolate) as it may increase side effects.Contact your doctor if you experience nausea, vomiting, insomnia, palpitations, or seizures.Inform all healthcare providers you are taking this medication.Do not stop suddenly without consulting your doctor.
Take THEOCLEAR-200 exactly as prescribed; do not change dose without consulting your doctor.Do not crush or chew sustained-release tablets; swallow whole.Avoid large amounts of caffeine (coffee, tea, chocolate, cola) as it may increase side effects.Inform your doctor if you experience nausea, vomiting, insomnia, tremors, or rapid heartbeat.Do not smoke or start/stop smoking without telling your doctor, as it affects theophylline levels.Keep all appointments for blood tests to monitor theophylline levels.Store at room temperature away from moisture and heat.